Lactic acid bacteria strain composition for improving chronic kidney disease and its application
By using mixtures of lactic acid bacteria strains such as Lactobacillus acidophilus as medical components, the problem that the prior art cannot effectively reduce urotoxin and its precursors and slow down renal tissue lesions is solved, and the effect of significantly improving chronic kidney disease and renal function is achieved. And avoid the side effects of common treatment methods.
Patent Information
- Application Number
- CN202410499409.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-04-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-04-24
AI Technical Summary
The prior art cannot effectively reduce urotoxin and its precursors and slow down renal tissue lesions, and common treatment methods have side effects and adverse reactions to patients with chronic kidney disease.
BR631, a thermophilus subsp.infantis, and a thermophilus subsp.infantis, were used. Salivarius subsp.thermophilus) A mixture of lactic acid bacteria strains composed of Hot-06, combined with a pharmaceutically acceptable carrier, is used as a pharmaceutical composition in oral dosage forms to improve chronic kidney disease.
The composition produces organic acids in the gastrointestinal intestinal intestinal intestinal pH, inhibits the growth of acid-tolerant microorganisms, and reduces the concentration of urea nitrogen in the blood and slows down the burden of renal metabolic ammonia by producing short-chain fatty acids and converting urea into ammonia. Improve chronic kidney disease and renal function.
Smart Images

Figure CN118384188B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of microbial preparations, and in particular relates to a lactic acid bacteria strain composition for improving chronic kidney disease and an application thereof. Background Art
[0002] The kidneys are responsible for performing a variety of physiological functions in the human body, including: controlling the homeostasis of fluids and electrolytes in the body and excreting nitrogenous wastes, namely uremic toxins (such as urea, creatinine and indoxylsulfate). When kidney function is gradually impaired due to disease, aging or poor eating habits, it cannot effectively remove nitrogenous wastes accumulated in the blood or renal tissue is repeatedly inflamed and renal fibrosis occurs, which will cause chronic kidney disease (CKD) (also known as chronic renal failure).
[0003] Currently, there is no clinical method that can completely cure CKD. It can only be prevented from further deterioration by changing lifestyle and eating habits and controlling blood sugar and blood pressure. Patients with severe renal impairment need further dialysis or kidney transplantation. However, these treatment options not only fail to achieve the desired therapeutic effect, but may also cause serious side effects and adverse reactions in patients. Therefore, researchers in this field are committed to developing drugs that can effectively treat CKD without producing undesirable side effects.
[0004] Lactic acid bacteria (LAB) are generally recognized as safe (GRAS) and are familiar and widely used probiotics. Common lactic acid bacteria include: Lactobacillus, Lactococcus, Pediococcus, Enterococcus, Streptococcus, Bifidobacterium, Bacillus and Leuconostoc, etc.
[0005] There have been studies on the application of lactic acid bacteria strains in the treatment of chronic kidney disease. For example, in Wang IK et al. (2021), Front. Nutr., doi: 10.3389 / fnut.2021.661794, Wang IK et al. administered a probiotic composition containing Lactobacillus acidophilus TYCA06, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium bifidum VDD088 to mice with adenine-induced CKD and found that the probiotic composition can effectively reduce the blood urea nitrogen (BUN) and creatinine levels in mice with CKD. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide a microbial composition, which has the effect of reducing uremic toxins and their precursors and slowing down renal tissue lesions to improve chronic kidney disease (CKD) and enhance renal function, and its effect is significantly better than the conventional probiotic combination.
[0007] The technical scheme of the present invention is a lactic acid bacteria strain pharmaceutical composition for improving chronic kidney disease, which comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 are all preserved in the General Microbiological Center of China Microorganism Culture Collection Administration (CGMCC), and the preservation numbers are CGMCC No. 21382, CGMCC No. 28231, CGMCC No. 28383, CGMCC No. 28384, CGMCC No. 28385, CGMCC No. 28386, CGMCC No. 28387, CGMCC No. 28388, CGMCC No. 28389, CGMCC No. 28381, CGMCC No. 283 ... No.26243 and CGMCC No.28232.
[0008] Among them, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is: 1:0.14:0.14:0.14~1:7:7:7, or 1:0.03:0.03:0.03~1:30:30:30.
[0009] Preferably, the above-mentioned bacterial count ratio is 1:1:1:1, 1:1:1:30, 1:1:30:1, 1:30:1:1, 30:1:1:1, 1:1:1:7, 1:1:7:1, 1:7:1:1 or 7:1:1:1.
[0010] Furthermore, the bacterial concentration in the pharmaceutical composition is 10 6 ~10 11 CFU / mL.
[0011] Preferably, the bacterial concentration is 10 9 CFU / mL.
[0012] Furthermore, the lactic acid bacteria strain pharmaceutical composition also contains prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
[0013] Specifically, the carrier comprises a solvent, a buffer, an emulsifier, a suspending agent, a decomposing agent, a disintegrant, a dispersing agent, a binder, an excipient, a stabilizer, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome or a combination thereof.
[0014] Particularly, the dosage form of the lactic acid bacteria strain pharmaceutical composition is an oral preparation.
[0015] The present invention also provides an application of the above-mentioned lactic acid bacteria strain pharmaceutical composition in the preparation of a drug for improving chronic kidney disease, wherein the lactic acid bacteria strain pharmaceutical composition comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 are all deposited in the General Microbiological Center of China National Committee for the Administration of Microbiological Culture Collection (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No. 21383 and CGMCC No. 21384, respectively. No.28231, CGMCC No.26243 and CGMCC No.28232.
[0016] Among them, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is: 1:0.14:0.14:0.14~1:7:7:7, or 1:0.03:0.03:0.03~1:30:30:30.
[0017] Preferably, the above-mentioned bacterial count ratio is 1:1:1:1, 1:1:1:30, 1:1:30:1, 1:30:1:1, 30:1:1:1, 1:1:1:7, 1:1:7:1, 1:7:1:1 or 7:1:1:1.
[0018] Specifically, based on the total bacterial count, the lactic acid bacteria strain mixture contains: 3% to 90% of Lactobacillus acidophilus PCo-96, 3% to 90% of Lactobacillus casei ZE-2, 3% to 90% of Bifidobacterium longum infantis subspecies BR631, and 3% to 90% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0019] Preferably, based on the total bacterial count, the lactic acid bacteria strain mixture, the lactic acid bacteria strain medicine / food composition may contain: 10% to 70% of Lactobacillus acidophilus PCo-96, 10% to 70% of Lactobacillus casei ZE-2, 10% to 70% of Bifidobacterium longum infantis subspecies BR631 and 10% to 70% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0020] Among them, Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631, and Streptococcus salivarius subsp. thermophilus Hot-06 can be live or dead, concentrated or non-concentrated, liquid, paste, semi-solid, or solid [for example, pellets, granules or powder], and can be heat-inactivated, frozen, dried, or freeze-dried [for example, in freeze-dried form or spray / fluid bed dried form].
[0021] Furthermore, the bacterial concentration in the pharmaceutical composition is 10 6 ~10 11 CFU / mL.
[0022] Preferably, the bacterial concentration is 10 9 CFU / mL.
[0023] Furthermore, the lactic acid bacteria strain pharmaceutical composition also contains prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
[0024] Specifically, the carrier comprises a solvent, a buffer, an emulsifier, a suspending agent, a decomposing agent, a disintegrant, a dispersing agent, a binder, an excipient, a stabilizer, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome or a combination thereof.
[0025] Particularly, the dosage form of the lactic acid bacteria strain pharmaceutical composition is an oral preparation.
[0026] The present invention also provides an application of a lactic acid bacteria strain composition as a pharmaceutical composition for preparing a renal function-improving composition, wherein the lactic acid bacteria strain pharmaceutical composition comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 are all deposited in the General Microbiological Center of China National Committee for the Administration of Microbiological Culture Collection (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No. 21383 and CGMCC No. 21384, respectively. No.28231, CGMCC No.26243 and CGMCC No.28232.
[0027] Among them, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is: 1:0.14:0.14:0.14~1:7:7:7, or 1:0.03:0.03:0.03~1:30:30:30.
[0028] Preferably, the above-mentioned bacterial count ratio is 1:1:1:1, 1:1:1:30, 1:1:30:1, 1:30:1:1, 30:1:1:1, 1:1:1:7, 1:1:7:1, 1:7:1:1 or 7:1:1:1.
[0029] Specifically, based on the total bacterial count, the lactic acid bacteria strain mixture contains: 3% to 90% of Lactobacillus acidophilus PCo-96, 3% to 90% of Lactobacillus casei ZE-2, 3% to 90% of Bifidobacterium longum infantis subspecies BR631, and 3% to 90% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0030] Preferably, based on the total bacterial count, the lactic acid bacteria strain mixture, the lactic acid bacteria strain medicine / food composition may contain: 10% to 70% of Lactobacillus acidophilus PCo-96, 10% to 70% of Lactobacillus casei ZE-2, 10% to 70% of Bifidobacterium longum infantis subspecies BR631 and 10% to 70% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0031] Among them, Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631, and Streptococcus salivarius subsp. thermophilus Hot-06 can be live or dead, concentrated or non-concentrated, liquid, paste, semi-solid, or solid [for example, pellets, granules or powder], and can be heat-inactivated, frozen, dried, or freeze-dried [for example, in freeze-dried form or spray / fluid bed dried form].
[0032] Furthermore, the bacterial concentration in the pharmaceutical composition is 10 6 ~10 11 CFU / mL.
[0033] Preferably, the bacterial concentration is 10 9 CFU / mL.
[0034] Furthermore, the lactic acid bacteria strain pharmaceutical composition also contains prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
[0035] Specifically, the carrier comprises a solvent, a buffer, an emulsifier, a suspending agent, a decomposing agent, a disintegrant, a dispersing agent, a binder, an excipient, a stabilizer, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome or a combination thereof.
[0036] Particularly, the dosage form of the lactic acid bacteria strain pharmaceutical composition is an oral preparation.
[0037] The present invention also provides a lactic acid bacteria strain food composition, comprising a lactic acid bacteria strain mixture and a physiologically acceptable carrier; the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 are all preserved in the General Microbiological Center of China National Committee for Microbiological Culture Collection (CGMCC), and the preservation numbers are CGMCC No. 21382, CGMCC No. 28231, CGMCC No. 26243 and CGMCC No. 26244, respectively. No.28232.
[0038] Among them, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is: 1:0.14:0.14:0.14~1:7:7:7, or 1:0.03:0.03:0.03~1:30:30:30.
[0039] Preferably, the above-mentioned bacterial count ratio is 1:1:1:1, 1:1:1:30, 1:1:30:1, 1:30:1:1, 30:1:1:1, 1:1:1:7, 1:1:7:1, 1:7:1:1 or 7:1:1:1.
[0040] Specifically, based on the total bacterial count, the lactic acid bacteria strain mixture contains: 3% to 90% of Lactobacillus acidophilus PCo-96, 3% to 90% of Lactobacillus casei ZE-2, 3% to 90% of Bifidobacterium longum infantis subspecies BR631, and 3% to 90% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0041] Preferably, based on the total bacterial count, the lactic acid bacteria strain mixture, the lactic acid bacteria strain medicine / food composition may contain: 10% to 70% of Lactobacillus acidophilus PCo-96, 10% to 70% of Lactobacillus casei ZE-2, 10% to 70% of Bifidobacterium longum infantis subspecies BR631 and 10% to 70% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0042] Among them, Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631, and Streptococcus salivarius subsp. thermophilus Hot-06 can be live or dead, concentrated or non-concentrated, liquid, paste, semi-solid, or solid [for example, pellets, granules or powder], and can be heat-inactivated, frozen, dried, or freeze-dried [for example, in freeze-dried form or spray / fluid bed dried form].
[0043] Furthermore, the bacterial concentration in the food composition is 10 6 ~10 11 CFU / mL.
[0044] Preferably, the bacterial concentration is 10 9 CFU / mL.
[0045] Furthermore, the lactic acid bacteria strain pharmaceutical composition also contains prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
[0046] Preferably, the physiologically acceptable carrier is a food.
[0047] Particularly, the food is a beverage, a functional beverage, a fermented food, an animal feed, a health food, a dessert or a dietary supplement.
[0048] Beneficial effects of the present invention: The present invention provides a microbial composition consisting of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06. The mixture of 4 different lactic acid bacteria strains can produce organic acids in the stomach and intestines to reduce the pH value in the intestinal environment, thereby inhibiting the growth of other acid-intolerant microorganisms, including some acid-intolerant pathogenic bacteria. At an appropriate pH value, lactobacillus can produce lactic acid and hydrogen peroxide, and even acetic acid and benzoic acid; bifidobacteria can produce short-chain fatty acids such as acetic acid, propionic acid and butyric acid. In addition, it also has the ability to convert urea into ammonia together, and consumes ammonia as the growth nitrogen source of the four lactic acid bacteria strains of the present invention, thereby reducing the urea nitrogen concentration in the blood and slowing down the burden of kidney metabolism of ammonia. Therefore, compared with a single strain composition, the lactic acid bacteria strain composition of the present invention includes a mixture of four different lactic acid bacteria strains for improving chronic kidney disease, improving renal function or maintaining renal function. The lactic acid bacteria strain composition of the present invention provides a new option for improving chronic kidney disease or maintaining renal function.
[0049] The Lactobacillus acidophilus PCo-96 of the present invention was deposited in the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration on December 16, 2020, with a deposit number of CGMCC No. 21382. The address of the deposit unit is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, Postal Code 100101.
[0050] The Lactobacillus casei ZE-2 strain of the present invention was deposited in the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration on August 23, 2023, with a deposit number of CGMCC No. 28231. The address of the deposit unit is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Postal Code 100101.
[0051] The Bifidobacterium longum subsp. infantis BR631 of the present invention was deposited in the General Microbiological Center (CGMCC) of the China Microbiological Culture Collection Administration on December 25, 2022, with a deposit number of CGMCC No. 26243. The address of the deposit unit is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, Postal Code 100101.
[0052] The Streptococcus salivarius subsp. thermophilus Hot-06 strain of the present invention was deposited in the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration on August 23, 2023, with a deposit number of CGMCC No. 28232. The address of the deposit unit is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, Postal Code 100101. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 The graph shows the changes in the indole content in the feces of the rats in each group of Example 2 over time. In the same group, when the data of different weeks are marked with different letters, it means that there are statistical differences between these data.
[0054] Figures 2 to 4 The graphs show the changes in the blood urea nitrogen, creatinine and inorganic phosphorus content of each group of rats in Example 2 over time. In the same group, when the data of different weeks are marked with different letters, it means that there are statistical differences between these data.
[0055] Figure 5 The results of observation of kidney tissues of rats in each group in Example 2 by hematoxylin-eosin staining are shown.
[0056] Figure 6 The urea nitrogen content measured in the blood of each group of rats in Example 3 is shown, wherein when the data of different groups are marked with different English letters, it means that there are statistical differences between these data.
[0057] Figure 7 The creatinine levels measured in the blood of the rats in each group in Example 3 are shown, wherein when the data of different groups are marked with different English letters, it means that there are statistical differences between these data. DETAILED DESCRIPTION
[0058] The present invention provides a lactic acid bacteria strain pharmaceutical composition for improving chronic kidney disease (CKD), which comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier. The lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06, which are all deposited in the General Microbiological Center of China Microorganism Culture Collection Administration (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No. 28231, CGMCC No. 26243 and CGMCC No. 28232. Preferably, the pharmaceutical composition can be a pharmaceutical composition in an oral dosage form.
[0059] The present invention provides another lactic acid bacteria strain food composition, which comprises a lactic acid bacteria strain mixture and a physiologically acceptable carrier. The lactic acid bacteria strain mixture comprises Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06, which are all deposited in the General Microbiological Center of China National Microbiological Culture Collection Committee (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No. 28231, CGMCC No. 26243 and CGMCC No. 28232. In a preferred embodiment of the present invention, the physiologically acceptable carrier may be a food.
[0060] Preferably, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is 1:0.03:0.03:0.03 (i.e. 30:1:1:1) to 1:30:30:30; more preferably, the bacterial count ratio is 1:1:1:1, 1:1:1:30, 1:1:30:1, 1:30:1:1 or 30:1:1:1.
[0061] Preferably, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is 1:0.14:0.14:0.14 (i.e. 7:1:1:1) to 1:7:7:7; more preferably, the bacterial count ratio is 1:1:1:1, 1:1:1:7, 1:1:7:1, 1:7:1:1 or 7:1:1:1.
[0062] In a preferred embodiment of the present invention, the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 in the lactic acid bacteria strain mixture is 1:1:1:1.
[0063] According to the present invention, based on the total bacterial count, the lactic acid bacteria strain mixture may include: 3% to 90% of Lactobacillus acidophilus PCo-96, 3% to 90% of Lactobacillus casei ZE-2, 3% to 90% of Bifidobacterium longum infantis subspecies BR631, and 3% to 90% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0064] Preferably, based on the total bacterial count, the lactic acid bacteria strain mixture, the lactic acid bacteria strain medicine / food composition may include: 10% to 70% of Lactobacillus acidophilus PCo-96, 10% to 70% of Lactobacillus casei ZE-2, 10% to 70% of Bifidobacterium longum infantis subspecies BR631 and 10% to 70% of Streptococcus salivarius thermophilus subspecies Hot-06.
[0065] According to the present invention, Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum subsp. infantis BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 can be live or dead, concentrated or non-concentrated, liquid, paste, semi-solid, or solid [e.g., pellets, granules or powder], and can be heat-inactivated, frozen, dried, or freeze-dried [e.g., in freeze-dried form or spray / fluid bed dried form].
[0066] According to the present invention, the bacterial concentration of the pharmaceutical composition or food composition is 10 6 ~10 11 In a preferred embodiment of the present invention, the bacterial concentration of the composition is 10 9 CFU / mL.
[0067] According to the present invention, the pharmaceutical composition or food composition may further include prebiotics, preferably, the prebiotics may include at least one of inulin, fructooligosaccharides, galactooligosaccharides, stachyose, isomaltooligosaccharides, mannooligosaccharides, chitosan, resistant dextrin, and citrus fiber. In a preferred embodiment of the present invention, the prebiotic is inulin.
[0068] In addition, the present invention also provides an application of the lactic acid bacteria strain composition as described above as a pharmaceutical composition for improving chronic kidney disease.
[0069] The present invention also provides a use of the lactic acid bacteria composition as described above as a pharmaceutical composition for improving renal function.
[0070] As used herein, "improving" or "ameliorating" means treating, preventing, reducing, alleviating, relieving, or controlling one or more clinical signs of a disease or disorder, as well as lowering, stopping, or reversing the progression of the severity of a condition or symptom being treated.
[0071] According to the present invention, the improvement of chronic kidney disease and renal function includes the reduction of the content of uremic toxins and their precursors.
[0072] According to the present invention, the uremic toxins include, but are not limited to: urea, creatinine, indoxyl derivatives [e.g., indoxyl sulfate, indole-3-acetic acid, kynurenine, kynurenic acid, melatonin, quinolinic acid and indoxyl glucuronide] and p-cresyl sulfate.
[0073] According to the present invention, the precursors of uremic toxins include, but are not limited to, indole, cresol, phenol, hippurate, and advanced glycation endproducts.
[0074] According to the present invention, the improvement of chronic kidney disease and renal function also includes a decrease in the content of the following renal function biochemical indicators: blood urea nitrogen (BUN) and inorganic phosphorus (IP).
[0075] According to the present invention, the types of food products may include, but are not limited to: beverages (e.g., tea, coffee), functional beverages, fermented foods, animal feeds, health foods, confectionery, and dietary supplements.
[0076] According to the present invention, the pharmaceutical composition can be manufactured into a dosage form suitable for oral administration using techniques well known to those skilled in the art, including, but not limited to: sterile powder, tablet, troche, lozenge, pellet, capsule, dispersible powder or granule, solution, suspension, emulsion, syrup, chewing gum, elixir, slurry and the like.
[0077] According to the present invention, the pharmaceutically acceptable carrier contained in the pharmaceutical composition can be a solvent, a buffer, an emulsifier, a suspending agent, a decomposer, a disintegrating agent, a dispersing agent, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome or a combination thereof. The selection and amount of these agents fall within the professional qualities and routine technical scope of those skilled in the art.
[0078] According to the present invention, the pharmaceutical composition may further comprise conventional additives for enhancing sensory properties (such as smell, flavor and appearance), including, but not limited to, flavoring agents, flavors and pigments.
[0079] The present invention also provides a method for improving chronic kidney disease, comprising administering a composition as described above to a subject in need thereof.
[0080] The present invention also provides a method for improving renal function, comprising administering a composition as described above to a subject in need thereof.
[0081] As used herein, the terms "administering" and "administration" are used interchangeably and mean introducing, providing or delivering a predetermined active ingredient to a subject by any appropriate route to perform its intended effect.
[0082] As used herein, the term "subject" means any mammal of interest, such as humans, monkeys, cows, sheep, horses, pigs, goats, dogs, cats, mice, and rats.
[0083] According to the present invention, the dosage and frequency of administration of the composition will vary depending on the severity of the disease to be improved, the route of administration, and the age, physical condition and response of the individual to be improved. Generally speaking, the pharmaceutical product according to the present invention can be administered orally in a single dose or divided into several doses.
[0084] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs. One skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to implement the present invention. Of course, the present invention is in no way limited to the methods and materials described.
[0085] All patents and references cited in this specification are incorporated herein by reference in their entirety. In the event of a conflict, the detailed description (including definitions) of this specification will prevail.
[0086] Although the present invention has been described with reference to the specific embodiments above, it is apparent that many modifications and variations can be made without departing from the scope and spirit of the invention. It is therefore intended that the present invention be limited only as indicated by the appended claims.
[0087] The present invention will be further described below in conjunction with examples. However, it should be understood that these examples are only for illustration and should not be construed as limitations on the implementation of the present invention.
[0088] Example
[0089] General experimental materials:
[0090] 1. Lactic acid bacteria strains:
[0091] The lactic acid bacteria strains used for efficacy evaluation in the following embodiments are separated by the applicant and entrusted by the Food Industry Research and Development Institute (FIRDI) to identify the strains, and have been deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration (No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, 100101). For clarity, the relevant information of each lactic acid bacteria strain (including: scientific name, deposit number, deposit date and separation source, etc.) has been integrated in Table 1 below.
[0092] Table 1 Relevant information of each lactic acid bacteria strain
[0093]
[0094] For comparison, three lactic acid bacteria strains disclosed in Wang IK et al. (2021) (same as above) were also used, and relevant information about these lactic acid bacteria strains (including: scientific name, preservation number and purchase source, etc.) has been integrated in Table 2 below.
[0095] Table 2 Relevant information of each lactic acid bacteria strain
[0096]
[0097] 2. Experimental Animals:
[0098] Male Sprague-Dawley (SD) rats (9 to 10 weeks old, weighing about 400 g) used in the following examples were purchased from Ulesco Biotech Co., Ltd. All experimental animals were housed in an independently air-conditioned animal room with a light and dark period of 12 hours each, a room temperature maintained at 22±2°C, and a relative humidity maintained at 62±5%, and water and feed were adequately supplied. The animal husbandry environment, treatment, and all experimental procedures were in accordance with the standards of the Institutional Animal Care and Use Committee of the inventor's service unit.
[0099] General experimental methods:
[0100] Statistical analysis:
[0101] In the following examples, the experiments of each group were repeated at least 3 times, and the experimental data obtained were expressed as mean ± standard error of the mean (SEM). The differences between the experimental data of each group were analyzed by using GraphPad Prism 5 software (GraphPad Prism 5 Software, San Diego, CA) to perform Student's t-test, one-way analysis of variance (one-way ANOVA) and two-way analysis of variance (two-way ANOVA), followed by Tukey's test to evaluate the differences between the groups. If the statistical comparison result obtained was p < 0.05, it represented statistical significance.
[0102] Example 1 Preparation of a mixture of four lactic acid bacteria strains of the present invention
[0103] First, Lactobacillus acidophilus PCo-96 (BCRC911173), Lactobacillus casei ZE-2 (BCRC 911174), Bifidobacterium longum infantis subsp. BR631 (BCRC 911172), and Streptococcus salivarius thermophilus subsp. Hot-06 (BCRC 911181) described in item 1 of the above "General Experimental Materials" were inoculated into DifcoTM MRS (De Man, Rogosa and Sharpe) medium at an inoculum volume of 1% (v / v), and cultured at 37°C for 20 hours. Afterwards, the four cultures obtained were centrifuged at 2750g for 20 minutes at 4°C, the supernatant was then removed, and the pellets obtained were freeze-dried to obtain bacterial powder of each lactic acid bacteria strain. Next, an appropriate amount of sterilized water was used to suspend the powder of each lactic acid bacteria strain to adjust the bacterial concentration to 109 CFU / mL (the bacterial count was performed using a plate count medium), and then the powders were mixed uniformly in equal volumes to obtain a mixed bacterial solution.
[0104] Example 2 Evaluation of the efficacy of the mixture containing four lactic acid bacteria strains of the present invention in improving chronic kidney disease (CKD)
[0105] In this example, adenine was used to induce CKD in rats to evaluate the therapeutic efficacy of the mixture containing 4 lactic acid bacteria strains of the present invention.
[0106] Experimental methods:
[0107] A. Induction of CKD and administration of lactic acid bacteria strains:
[0108] First, male SD rats were randomly divided into 3 groups, including 1 normal control group, 1 pathological control group, and 1 experimental group (n=6 in each group). Then, the rats in the pathological control group and the experimental group were administered with 0.025% adenine (Sigma-Aldrich) (dissolved in ddH2O) by oral gavage, while the rats in the normal control group were administered with an equal volume of ddH2O. Each group of rats was administered once a day for a total of 5 weeks.
[0109] Starting from the 6th week after the start of adenine administration, the experimental group of rats was administered with the mixed bacterial solution obtained in Example 1 above (dosage of 109 CFU / rat) and inulin (Sigma-Aldrich) (dosage of 1 mg / kg) by oral gavage, while the normal control group and the pathological control group of rats were administered with an equal volume of ddH2O. Each group of rats was administered once a day for a total of 10 weeks.
[0110] B. Observation of patterns:
[0111] The morphology of rats in each group was observed before the start of adenine administration (ie, week 0) and at the end of each week after the start of adenine administration.
[0112] C. Determination of indole content in feces:
[0113] Before the start of adenine administration and at the end of the 5th, 7th and 15th weeks after the start of adenine administration, feces of rats in each group were collected as test samples, and the indole content was determined using Kovács analysis according to the method described in Darkoh C. et al. (2015), Appl. Environ. Microbiol., 81: 8093-8097.
[0114] Afterwards, the experimental data obtained were analyzed according to the method described in the first item "Statistical analysis" of the "General experimental methods" above.
[0115] D. Evaluation of biochemical indicators of renal function in the blood:
[0116] Blood was collected from the caudal vein of each group of rats by venipuncture bleeding before the start of adenine administration and at the end of the 5th, 7th and 15th weeks after the start of adenine administration. The blood samples were then allowed to stand at 4°C for 30 to 60 minutes and then centrifuged at 3000 rpm for 30 minutes at 4°C. The serum samples obtained were commissioned to Bio-Cando Incorporation for analysis of renal function biochemical indicators, including the determination of blood ureanitrogen (BUN), creatinine and inorganic phosphorus (IP).
[0117] Afterwards, the experimental data obtained were analyzed according to the method described in the first item "Statistical analysis" of the "General experimental methods" above.
[0118] E. Histopathological examination of kidney tissue:
[0119] At the end of the 15th week after the start of adenine administration, the rats in each group were sacrificed by exsanguination after anesthesia, and then the kidney tissues of the rats in each group were removed and fixed with 10% formalin at room temperature. The fixed tissue samples were then embedded with paraffin and sliced to obtain tissue sections with a thickness of 3 μm. If all rats in a group died before the 15th week, the kidney tissues were removed after death to prepare the above tissue sections.
[0120] Afterwards, the obtained tissue sections were stained with hematoxylin-eosin according to a technique well known and commonly used by a person skilled in the art, and then observed and photographed using an optical microscope (Invitrogen) at a magnification of 400 times.
[0121] result:
[0122] A. Observation of patterns:
[0123] From the 0th to the 5th week after the start of adenine administration, the body size of the rats in the normal control group can be observed to increase significantly over time, while the body size of the rats in the pathological control group and the experimental group did not show obvious changes. From the 6th week after the start of adenine administration, in particular, the body size of the rats in the pathological control group decreased over time, and all died in the 10th week after the start of adenine administration. In contrast, the rats in the experimental group not only did not die, but their body size gradually increased over time.
[0124] B. Determination of indole content in feces:
[0125] Figure 1 The indole content measured in the feces of each group of rats changes over time. Figure 1 It can be seen that before the administration of adenine, there was no significant difference in the indole content in the feces of the groups. At the end of the fifth week after the administration of adenine, the indole content in the feces of the rats in the pathological control group and the experimental group increased significantly, indicating that adenine successfully induced CKD and caused an abnormal increase in the precursors of uremic toxins in the feces. At the end of the seventh week, only the indole content in the feces of the rats in the experimental group decreased significantly, and continued to decrease until the end of the 15th week.
[0126] C. Evaluation of biochemical indicators of renal function in the blood:
[0127] Figures 2 to 4 The graphs show the changes in the blood urea nitrogen, creatinine and inorganic phosphorus content of each group of rats over time. Figures 2 to 4 It can be seen that before the administration of adenine, there was no significant difference in the blood urea nitrogen, creatinine and inorganic phosphorus levels of each group. At the end of the 5th week after the administration of adenine, the blood urea nitrogen, creatinine and inorganic phosphorus levels of the rats in the pathological control group and the experimental group increased significantly, indicating that adenine successfully induced CKD and caused the accumulation of urea toxins in the blood. At the end of the 7th week, only the blood urea nitrogen, creatinine and inorganic phosphorus levels of the rats in the experimental group decreased significantly, and continued to decrease until the end of the 15th week.
[0128] D. Histopathological examination of kidney tissue:
[0129] Figure 5 The results of hematoxylin-eosin staining of the kidney tissues of the rats in the normal control group and the experimental group at the end of the 15th week after the start of adenine administration are shown. As for the rats in the pathological control group, since they died in the 10th week, the kidney tissues were taken out immediately after death for staining. Figure 5 It can be seen that compared with the normal control group, the rats in the pathological control group had a large amount of fibrosis in the kidney tissue, which means that adenine successfully induced CKD and caused kidney tissue lesions. Compared with the pathological control group, the fibrosis in the kidney tissue of the rats in the experimental group was significantly reduced.
[0130] Based on the above experimental results, it can be seen that the mixture containing 4 lactic acid bacteria strains of the present invention can effectively reduce uremic toxins and their precursors and slow down kidney tissue pathology, and is therefore believed to improve CKD and enhance renal function.
[0131] Example 3 Comparison of the efficacy of mixtures containing different lactic acid bacteria strains in improving CKD
[0132] In order to evaluate the effectiveness of the mixture containing 4 lactic acid bacteria strains of the present invention in improving CKD compared with a probiotic combination known to reduce the deterioration of renal function, the applicant selected the probiotic combination disclosed in Wang IK et al. (2021) (same as above) for experiment.
[0133] Experimental Materials:
[0134] 1. Prepare a conventional probiotic combination containing three lactic acid bacteria strains:
[0135] Lactobacillus acidophilus TYCA06, Bifidobacterium longum infantis subspecies BLI-02, and Bifidobacterium bifidum VDD088 described in Item 1 of the "General Experimental Materials" above were inoculated into DifcoTMMRS medium at an inoculum volume of 1% (v / v), and cultured at 37°C for 20 hours. Afterwards, the three cultures obtained were centrifuged at 2750g for 20 minutes at 4°C, and then the supernatant was removed, and then the obtained precipitate was freeze-dried to obtain the powder of each lactic acid bacteria strain. Next, an appropriate amount of sterilized water was used to suspend and adjust the powder of each lactic acid bacteria strain to a bacterial concentration of 109CFU / mL (the number of bacteria was counted using a plate counting medium), and then mixed with each other in the same volume to obtain a mixed bacterial solution.
[0136] Experimental methods:
[0137] A. Induction of CKD and administration of lactic acid bacteria strains:
[0138] First, male SD rats were randomly divided into 4 groups, including 1 normal control group, 1 pathological control group, 1 experimental group and 1 comparative experimental group (n=6 in each group). Then, the rats in the pathological control group, experimental group and comparative experimental group were administered with 0.025% adenine (dissolved in PBS) by oral gavage, while the rats in the normal control group were administered with an equal volume of PBS. Each group of rats was administered once a day for a total of 42 days.
[0139] In addition, starting from the first day after the administration of adenine, the experimental group of rats was administered with the mixed bacterial solution obtained in Example 1 above (dosage of 109 CFU / rat) and inulin (dosage of 1 mg / kg) by oral gavage, and the comparative experimental group of rats was administered with the mixed bacterial solution obtained in Item 1 of the above "Experimental Materials" (dosage of 109 CFU / rat), while the normal control group and the pathological control group of rats were administered with an equal volume of PBS. Each group of rats was administered once a day for a total of 42 days.
[0140] B. Evaluation of biochemical indicators of renal function in blood:
[0141] At the end of the 42nd day after the start of adenine administration, blood was collected from the tail vein of each group of rats by venipuncture. The blood samples were then allowed to stand at 4°C for 30 to 60 minutes, and then centrifuged at 3000 rpm for 30 minutes at 4°C. The serum samples obtained were commissioned to Hongming Technology Co., Ltd. for analysis of renal function biochemical indicators, including the determination of urea nitrogen (BUN) and creatinine content.
[0142] Afterwards, the experimental data obtained were analyzed according to the method described in the first item "Statistical analysis" of the "General experimental methods" above.
[0143] result:
[0144] Figure 6 and Figure 7 The urea nitrogen and creatinine levels in the blood of each group of rats are shown. Figure 6 and Figure 7 It can be seen that compared with the normal control group, the blood urea nitrogen and creatinine levels of the rats in the pathological control group were significantly increased, which means that adenine successfully induced CKD and caused the accumulation of urea toxins in the blood. Compared with the pathological control group, the blood urea nitrogen and creatinine levels of the rats in the experimental group were significantly reduced, while the comparative experimental group only had a slight decrease in blood urea nitrogen levels.
[0145] These experimental results show that the mixture containing four lactic acid bacteria strains of the present invention is significantly more effective than the conventional probiotic combination in improving CKD.
[0146] It should be noted that the lactic acid bacteria composition of the present invention is a mixture of 4 different lactic acid bacteria strains, which produce organic acids in the stomach and intestines to reduce the pH value in the intestinal environment, thereby inhibiting the growth of other acid-intolerant microorganisms, including some acid-intolerant pathogenic bacteria. For example, at an appropriate pH value, lactobacilli can produce lactic acid and hydrogen peroxide, and even acetic acid and benzoic acid; bifidobacteria can produce short-chain fatty acids such as acetic acid, propionic acid and butyric acid.
[0147] Continuing with the above description, in a preferred embodiment, the prebiotics further included in the lactic acid bacteria composition of the present invention can also promote the growth of the four lactic acid bacteria strains in the lactic acid bacteria composition of the present invention and other intestinal beneficial bacteria, and the prebiotics can be metabolized into different short-chain fatty acids, and these short-chain fatty acids have a wide range of antibacterial effects on pathogens and reduce inflammation and oxidation processes in the body.
[0148] In addition, the four lactic acid bacteria strains in the lactic acid bacteria strain composition of the present invention have the ability to convert urea into ammonia together, and consume ammonia as the growth nitrogen source of the four lactic acid bacteria strains of the present invention, thereby reducing the concentration of urea nitrogen in the blood and alleviating the burden of kidney metabolism of ammonia. Therefore, compared with a single strain composition, the lactic acid bacteria strain composition of the present invention comprising a mixture of four different lactic acid bacteria strains will have a better effect on improving chronic kidney disease, improving renal function or maintaining renal function.
[0149] All patents and references cited in this specification are incorporated herein by reference in their entirety. In the event of a conflict, the detailed description of this specification (including definitions) will prevail.
[0150] Although the present invention has been described with reference to the above specific embodiments, it is apparent that many modifications and variations can be made without departing from the scope and spirit of the invention. It is therefore intended that the present invention be limited only by the claims appended hereto.
Claims
1. A lactic acid bacteria strain pharmaceutical composition for improving chronic kidney disease, characterized in that: It comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; wherein the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus ( Lactobacillus acidophilus )PCo-96, Lactobacillus casei( Lacticaseibacillus casei )ZE-2, Bifidobacterium longum subsp. infantis ( Bifidobacterium longum subsp. infantis )BR631 and Streptococcus salivarius subsp. thermophilus ( Streptococcus salivarius subsp. thermophilus )Hot-06; the preservation numbers of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 are CGMCC No. 21382, CGMCC No.28231, CGMCC No.26243 and CGMCC No.28232, respectively; the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is 1:1:1:
1.
2. The lactic acid bacteria strain pharmaceutical composition according to claim 1, characterized in that: The lactic acid bacteria strain pharmaceutical composition further comprises prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
3. The lactic acid bacteria strain pharmaceutical composition according to claim 1, characterized in that: The carrier comprises a buffer, an emulsifier, a suspending agent, a disintegrator, a disintegrating agent, a dispersing agent, a binder, an excipient, a stabilizer, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome or a combination thereof.
4. The lactic acid bacteria strain pharmaceutical composition according to claim 1, characterized in that: The dosage form of the lactic acid bacteria strain medicinal composition is an oral preparation.
5. Use of a lactic acid bacteria strain composition in the preparation of a pharmaceutical composition for improving chronic kidney disease, characterized in that: The lactic acid bacteria strain composition comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; wherein the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus ( Lactobacillus acidophilus )PCo-96, Lactobacillus casei( Lacticaseibacillus casei )ZE-2, Bifidobacterium longum subsp. infantis ( Bifidobacterium longum subsp. infantis )BR631 and Streptococcus salivarius subsp. thermophilus ( Streptococcus salivarius subsp. thermophilus )Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 are all deposited in the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No.28231, CGMCC No.26243 and CGMCC No.28232 respectively; the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is 1:1:1:
1.
6. The use according to claim 5, characterized in that: The lactic acid bacteria strain composition further comprises prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
7. The use according to claim 5, characterized in that: The dosage form of the lactic acid bacteria strain composition is an oral preparation.
8. Use of a lactic acid bacteria strain composition in the preparation of a pharmaceutical composition for improving renal function, characterized in that: The lactic acid bacteria strain composition comprises a lactic acid bacteria strain mixture and a pharmaceutically acceptable carrier; wherein the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus ( Lactobacillus acidophilus )PCo-96, Lactobacillus casei( Lacticaseibacillus casei )ZE-2, Bifidobacterium longum subsp. infantis ( Bifidobacterium longum subsp. infantis )BR631 and Streptococcus salivarius subsp. thermophilus ( Streptococcus salivarius subsp. thermophilus )Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 are all deposited in the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No.28231, CGMCC No.26243 and CGMCC No.28232 respectively; the bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is 1:1:1:
1.
9. The use according to claim 8, characterized in that: The lactic acid bacteria strain composition further comprises prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
10. The use according to claim 8, characterized in that: The dosage form of the lactic acid bacteria strain composition is an oral preparation.
11. A lactic acid bacteria food composition, characterized in that: The invention comprises a lactic acid bacteria strain mixture and a physiologically acceptable carrier; wherein the lactic acid bacteria strain mixture comprises Lactobacillus acidophilus ( Lactobacillus acidophilus )PCo-96, Lactobacillus casei( Lacticaseibacillus casei )ZE-2, Bifidobacterium longum subsp. infantis ( Bifidobacterium longum subsp. infantis )BR631 and Streptococcus salivarius subsp. thermophilus ( Streptococcus salivarius subsp. thermophilus )Hot-06; Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subsp. BR631 and Streptococcus salivarius subsp. thermophilus Hot-06 are all deposited in the General Microbiology Center of China Microorganism Culture Collection (CGMCC), and the deposit numbers are CGMCC No. 21382, CGMCC No.28231, CGMCC No.26243 and CGMCC No.28232 respectively.
12. The lactic acid bacteria food composition according to claim 11, characterized in that: The bacterial count ratio of Lactobacillus acidophilus PCo-96, Lactobacillus casei ZE-2, Bifidobacterium longum infantis subspecies BR631 and Streptococcus salivarius thermophilus subspecies Hot-06 in the lactic acid bacteria strain mixture is: 1:0.14:0.14:0.14~1:7:7:7, or 1:0.03:0.03:0.03~1:30:30:
30.
13. The lactic acid bacteria food composition according to claim 11, characterized in that: The lactic acid bacteria strain composition further comprises prebiotics, which are at least one of inulin, fructooligosaccharide, galacto-oligosaccharide, stachyose, isomaltooligosaccharide, manno-oligosaccharide, chitosan, resistant dextrin and citrus fiber.
14. The lactic acid bacteria food composition according to claim 11, characterized in that: The physiologically acceptable carrier is a food.
15. The lactic acid bacteria food composition according to claim 14, characterized in that: The food is a beverage, a fermented food, an animal feed, a health food, a dessert or a dietary supplement.
